Navigation Links
Metabolix Announces Second Quarter 2014 Financial Results

CAMBRIDGE, Mass., Aug. 6, 2014 /PRNewswire/ -- Metabolix, Inc. (NASDAQ: MBLX), an advanced biomaterials company focused on sustainable solutions for the plastics and chemicals industries, today reported financial results for the three months ended June 30, 2014.

"As announced earlier this week, we have entered into a private placement agreement for $25 million of new equity financing, contingent upon obtaining a financial viability exception for the transaction from NASDAQ. Assuming we get the NASDAQ exception, we plan to deploy this capital to continue executing our business plan and building an intermediate-scale specialty polymers business based on our PHA biopolymer additives, that will serve as the foundation for our longer-range plans and the future growth of our business," said Joseph Shaulson, president and CEO of Metabolix.

"Operationally, we made good progress during the second quarter, as key customers ramped up commercial-scale trials of our PHA biopolymer products and we increased our pipeline of customers testing products in a variety of applications," Shaulson continued. "In the past several months, we have seen increasing interest and engagement with potential customers in the areas of PVC, PLA, latex coatings and micropowders, which underscores the value proposition of our innovative PHA products.

"We remain focused on securing financing, building market demand for our PHA products, and on having manufacturing up and running in 2015 to support an intermediate-scale biopolymers business. Once the private placement is completed, we plan to move forward with a preliminary engineering study and implementation planning for the retrofit of an existing contract manufacturing facility we have targeted for commercial PHA production. Successful completion of this study will enable us to progress to a detailed budget, definitive schedule and commercial cohort-term investments13,01922,509Net cash provided by investing activities11,41111,634Cash flows from financing activitiesProceeds from options exercised30014Net cash provided by financing activities 30014Effect of exchange rate changes on cash and cash equivalents(32)(18)Net (decrease) in cash and cash equivalents(2,167)(2,664)Cash and cash equivalents at beginning of period7,69814,572Cash and cash equivalents at end of period$



ntract for PHA manufacturing startup in 2015," Shaulson added.

SECOND QUARTER 2014 FINANCIAL OVERVIEWMetabolix manages its finances with an emphasis on cash flow and deploys its financial resources in a disciplined manner to achieve its key strategic objectives and to maximize value from its technology and product portfolio. The Company ended the second quarter of 2014 with $5.5 million in unrestricted cash and cash equivalents. The Company's net cash used in operating activities during the second quarter of 2014 was $4.9 million, compared with $5.8 million in the second quarter of 2013.Metabolix requires significant additional funding. Earlier in 2014, the Company indicated it would seek to raise $50 to $60 million to fund its business plan and that such financing might be accomplished in stages.  On August 4, 2014, Metabolix announced that it entered into a private placement agreement with investors for the sale of an aggregate of $25 million of Company securities. The closing of the private placement is subject to the Company obtaining a financial viability exception from certain NASDAQ shareholder approval requirements under Rule 5635(f) of the NASDAQ Stock Market Listing Rules, as well as other customary closing conditions. 

For the second quarter of 2014, the Company reported a net loss of $7.2 million, or $0.21 per share, compared with a net loss of $7.9 million, or $0.23 per share, for the second quarter of 2013.

Total revenue in the second quarter of 2014 was $1.2 million, compared with $1.7 million for the second quarter of 2013. Second quarter 2014 revenue consisted primarily of revenue from product sales and government grants. Biopolymer product orders of $0.6 million were shipped and billed during the quarter. The Company recognized $0.7 million in product revenue during the quarter, primarily from product shipments made during the first quarter of 2014, compared with $0.8 million in product revenue recognized during the second quarter of 2013. Cost of product revenue was $0.8 million during the quarter ended June 30, 2014 compared with $1.2 million for the comparable period in 2013.

Research and development expenses were $4.5 million for the second quarter of 2014, compared with $4.9 million for the same period in 2013. Selling, general and administrative expenses were $3.2 million and $3.4 million for the second quarters of 2014 and 2013, respectively.

For the first half of 2014, the Company reported a net loss of $15.4 million, or $0.44 per share, compared with a net loss of $14.6 million, or $0.43 per share, for the first half of 2013.

Total revenue during the first six months of 2014 was $2.2 million, compared with $3.6 million for the comparable period in 2013. Cost of product revenue was $1.5 million during the six months ended June 30, 2014, compared with $1.8 million for the comparable period in 2013.

Research and development expenses were $9.4 million during the first six months of 2014, compared with $9.8 million for the same period in 2013. Selling, general and administrative expenses were $6.8 million for the six-month period ended June 30, 2014 compared with $6.7 million for the first six months of 2013. 

The Company's net cash used in operating activities during the first half of 2014 was $13.8 million, which represents a decrease in cash used for operating activities from cash use of $14.3 million for the comparable period in 2013. 

Conference Call Information Metabolix management will host a conference call today at 4:30 p.m. (ET) to discuss the results of the second quarter. The Company also will provide an update on the business and answer questions from the investment community. A live webcast of the call with slides can be accessed through the Company's website at in the investor relations section. To participate in the call, dial toll-free 877-709-8155 or 201-689-8881 (international).

To listen to a telephonic replay of the conference call, dial toll-free 877-660-6853 or 201-612-7415 (international) and enter pass code 13588304. The replay will be available beginning at 7:30 p.m. (ET) on Wednesday, August 6, 2014 and will last through 11:59 p.m. (ET) on Wednesday, August 20, 2014. In addition, the webcast will be archived on the Company's website in the investor relations section.

About MetabolixMetabolix, Inc. is an advanced biomaterials company focused on sustainable solutions for the plastics and chemicals industries. The Company is developing and commercializing a family of high-performance biopolymers targeted at applications for performance additives that can improve performance and/or reduce cost in other material systems such as PVC, PLA and coated paper. Metabolix also is developing platforms for biobased chemicals based on its novel "FAST" recovery process and for co-producing plastics, chemicals and energy from crops. Metabolix has established an industry-leading intellectual property portfolio that, together with its knowledge of advanced industrial practice, provides a foundation for industry collaborations.

For more information, please visit  (MBLX-E)

Safe Harbor for Forward-Looking Statements This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, statements about the terms, timing, completion and effects of the proposed financing and the Company's intended use of proceeds therefrom, statements regarding the Company's business plans and strategies; expectations for establishing commercial PHA biopolymer manufacturing; expected market demand and commercialization plans for the Company's PHA biopolymer products; expected future financial results and cash requirements; plans for obtaining additional funding; plans and expectations that depend on the Company's ability to continue as a going concern; and expectations for future research, product development and collaborations constitute forward-looking statements.  Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Metabolix's filings with the Securities and Exchange Commission, including its 10-K for the year ended December 31, 2013 filed on March 28, 2014. Without limiting the generality of the foregoing, the Company may not be able to complete the private placement because of a number of factors, including the failure to obtain the NASDAQ financial viability exception.  Based on current projections, the Company anticipates that, unless by mid-August, 2014, it is reasonably likely that it will be able to obtain additional funding by August 31, 2014, the Company will be forced to initiate steps to cease operations. Even if the financing is consummated, the Company's future growth plans may not be successful.  Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

Metabolix Inquiries:  Lynne H. Brum, (617) 682-4693,


 METABOLIX, INC.CONDENSED CONSOLIDATED STATEMENT OF OPERATIONSUNAUDITED(in thousands, except share and per share data)Three Months EndedSix Months EndedJune 30,June 30,2014201320142013Revenue:Product revenue$




1,611Grant revenue4835849501,308Research and development revenue-238-618License fee and royalty revenue256288111Total revenue1,1701,7062,2393,648Costs and expenses:Cost of product revenue7741,1961,4691,753Research and development expenses4,4794,9459,3799,802Selling, general, and administrative expenses3,1563,4226,7906,734Total costs and expenses8,4099,56317,63818,289Loss from operations(7,239)(7,857)(15,399)(14,641)Other income (expense):Interest income, net212733Other income (expense), net-(21)2(20)Total other income (expense), net2(9)913Net loss$




(14,628)Net loss per share:Basic$








(0.43)Number of shares used in per share calculations:Basic34,989,14234,434,27134,898,47334,393,998Diluted34,989,14234,434,27134,898,47334,393,998 METABOLIX, INC.CONDENSED CONSOLIDATED BALANCE SHEETUNAUDITED(in thousands)June 30,December 31,20142013AssetsCash, cash equivalents $


7,698Short-term investments-11,511Inventory3,1624,074Other current assets1,4081,948Restricted cash619619Property and equipment, net560793Other assets9595Total assets$


26,738Liabilities and Stockholders' EquityAccounts payable and accrued liabilities$


5,471Short-term deferred revenue727669Current portion of deferred rent-55Other long-term liabilities150145Total liabilities4,5116,340Total stockholders' equity6,86420,398Total liabilities and stockholders' equity$


26,738 METABOLIX, INC.CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWSUNAUDITED(in thousands)Six Months Ended June 30,20142013Cash flows from operating activitiesNet loss$


(14,628)Adjustments to reconcile net loss to cash used in operating activities:Depreciation 333531Charge for 401(k) company common stock match259268Stock-based compensation1,3791,677Inventory impairment228271Changes in operating assets and liabilities:Inventory684(263)Accounts payable(147)(1,131)Accrued expenses(1,740)(345)Deferred revenue58(538)Other operating assets and liabilities490(136)Net cash used in operating activities(13,846)(14,294)Cash flows from investing activitiesPurchase of property and equipment(100)(270)Change in restricted cash-(25)Purchase of investments(1,508)(10,580)Proceeds from sale and maturity of s

SOURCE Metabolix, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolix, Inc. Enters into Private Placement Agreement with Investors to Raise $25 Million in Equity Financing
2. Metabolix Announces Third Quarter 2013 Financial Results
3. Metabolix Announces Second Quarter 2013 Financial Results
4. Metabolix Announces Promotion of Johan van Walsem to Chief Operating Officer
5. Metabolix Executives to Present at Leading Industry Conferences
6. Generex Announces Publication of AE37 Prostate Cancer Vaccine Study
7. Organovo Announces Appointment of Gregory T. Lucier as Corporate Advisor
8. Nerium Internationalâ„¢ Expands to Mexico and Builds Executive Team, Top Skincare Company Announces Its Arrival in Mexico by October
9. HRTTreatments / Natural Health Research Announces New Intuitive Online Hormone Test, Allowing Clients to Evaluate Possible Hormone Imbalances Easily Online
10. Sangamo BioSciences Announces Presentation At The 2014 Wedbush Securities Life Sciences Management Access Conference
11. ViaDerma, Inc. Announces Strategic Partnership With The Brewer Group
Post Your Comments:
(Date:10/8/2015)... ... 2015 , ... Cystic fibrosis (CF) is a genetic disease ... results in dysfunction of the lungs and the gastrointestinal (GI) tract. In CF ... very difficult to clear, blocks the airways and the glands, and creates an ...
(Date:10/7/2015)... ... , ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal Stem Cells ... 3:50 pm to 4:30 pm. , Dr. Riordan is one of the early pioneers ... the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute of Regenerative ...
(Date:10/7/2015)... Oct. 7, 2015  ContraVir Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of targeted antiviral ... offering of 5,000,000 shares of its common stock and ... Company,s common stock at a fixed combined price to ... and warrants will be issued separately.  The warrants will ...
(Date:10/7/2015)... Oct. 7, 2015   VWR (NASDAQ: ... laboratory products, services and solutions, announced today that ... specialty solvent company that performs high volume purification ... enhance VWR,s growing laboratory and production chemical manufacturing ... manufacturing customers. Manuel Brocke-Benz , President ...
Breaking Biology Technology:
... drive to make healthcare information technology interoperable across ... and a medical information technology company headquartered here ... is lending its expertise to developing an ... the healthcare industry. Specifically, the expertise of Damien ...
... Sonic Foundry, Inc. has announced that it ... the fourth quarter of 2006, its first cash-positive quarter ... been building toward profitability since moving into the rich-media ... which the company showcased new search technology. , ,The ...
... . - Following weeks of blistering criticism of its electronic ... Foundation Health Plan , Madison's Epic Systems Corp . ... defending its product. , ,Epic Systems, a medical software developer, ... its electronic records system, which Kaiser has re-branded with the ...
Cached Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The global glucose monitoring ... for 2015. So says a new report on the industry ... management segment dominate the market, followed by continuous glucose monitoring ... reports on the market for these products in its latest ... ...
(Date:9/28/2015)... 2015  The monitoring of vital signs, such ... is an essential component of patient assessment. Changes ... in a patient,s condition. However, in general care ... taken during routine observation rounds only once every ... between these observation rounds, the warning signs can ...
(Date:9/26/2015)... 2015  Results of a TactioRPM pilot project ... at the Stanford Medicine X Conference. In a ... Connected Health Devices and Pharmacogenomics", Roger Simard ... explain how senior patients equipped with connected health ... via the TactioRPM remote patient monitoring platform were ...
Breaking Biology News(10 mins):
... in traffic may cause a headache, but a delay ... of Missouri researchers have uncovered clues identifying which proteins ... and found that the proteins previously thought to play ... the nervous system develops will give researchers a better ...
... A team of Vanderbilt University Medical Center investigators has ... a new class of drugs for treating cancer., The ... phospholipase D (PLD), an enzyme that has been implicated ... colorectal., The new inhibitors, reported in the February issue ...
... gardening can offer enough moderate physical activity to keep older ... February in the journal HortScience , the researchers discovered ... older hands strong and nimble. "One of the things ... better hand strength and pinch force, which is a big ...
Cached Biology News:
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Ly-49C and Ly-49I Biotin Anti-Mouse clone 5E6, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Biology Products: